2022 World Conference on Lung Cancer (ePosters)-EP08.01-030. Nivolumab+Ipilimumab Vs Platinum-Based CT+Nivolumab In Advanced Lung Squamous-Cell Carcinoma: The Randomized SQUINT Trial

EP08.01-030. Nivolumab+Ipilimumab Vs Platinum-Based CT+Nivolumab In Advanced Lung Squamous-Cell Carcinoma: The Randomized SQUINT Trial

Back to course

Pdf Summary

The SQUINT trial investigated the efficacy of the combination of nivolumab and ipilimumab (NI) versus platinum-based chemotherapy and nivolumab (CT-Nivo) in patients with advanced/metastatic lung squamous cell carcinoma (LSCC). The trial included a total of 91 patients, with 45 assigned to the NI arm and 46 to the CT-Nivo arm. The majority of patients in both arms were male, with a performance status of 0-1 and a history of current or former smoking.<br /><br />The primary endpoint of the study was overall survival (OS) at 12 months. At the time of the analysis, with a median follow-up of 11 months, the OS rate at 1 year was 59.1% with NI and 62.4% with CT-Nivo. Median progression-free survival (PFS) was 3.8 months in the NI arm and 6.1 months in the CT-Nivo arm. The response rate was 22.2% with NI and 30.4% with CT-Nivo. Grade 3-4 treatment-related adverse events were more frequent in the CT-Nivo arm compared to the NI arm.<br /><br />The results of the SQUINT trial suggest that NI and CT-Nivo have similar activity in advanced LSCC. Both treatment strategies showed efficacy in terms of OS, PFS, and response rate. However, CT-Nivo was associated with a higher incidence of grade 3-4 adverse events, mainly hematological toxicity.<br /><br />This trial adds to the growing body of evidence supporting the use of immunotherapy combinations in the treatment of lung cancer. Further studies are needed to explore the long-term outcomes and potential predictors of response to NI and CT-Nivo in LSCC.

Asset Subtitle

Federico Cappuzzo

Meta Tag

Speaker Federico Cappuzzo

Topic Metastatic Non-small Cell Lung Cancer - Immunotherapy

Keywords

SQUINT trial

nivolumab

ipilimumab

platinum-based chemotherapy

lung squamous cell carcinoma

overall survival

progression-free survival

response rate

treatment-related adverse events

immunotherapy combinations